CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Advertisement

Solstice

Novel Drug-based Strategies for Cardiac Regeneration Following Myocardial Infarction

The human heart is one of nature’s engineering marvels, considering the requirement specifications for this fist-sized hollow organ that only weighs 250–300 grams. Delivering about five litres of blood at an average of 75 contractions per minute, it is required to perform without interruption. Considering the high performance demands, failings can occur beyond normal wear and tear in the heart’s electrical system, the valves, and the muscle itself. Of all complications leading to heart disease, ischemia – the insufficient supply of oxygen caused by restricted blood supply to the cardiac muscle – is the most prevalent. Dr Roman Schenk of Recardio explores the possible solutionsto this issue.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026